Symbiotec Pharmalab has debuted at Rs 978 on the BSE, down by 9.80 points or 0.99% from its issue price of Rs 988.
The scrip is currently trading at Rs. 982.05, down by 5.95 points or 0.60% from its issue price.
It has touched a high and low of Rs. 1,021.95 and Rs. 933.80 respectively. So far 8.15 lakh shares were traded on the counter.
The offering, which was open for subscription from August 24, 2026 to August 27, 2026 was subscribed 75.08 times. The issue price was fixed at Rs 988 per share i.e. at upper end of price band of Rs 938-988 apiece.
Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms - organic chemistry, biotechnology and complex injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1925.50 |
| Dr. Reddys Labs. | 1173.15 |
| Cipla | 1410.50 |
| Lupin | 2147.95 |
| Zydus Lifesciences | 1170.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: